PLA2G7 and metabolic syndrome: The American Association of Clinical Endocrinologists’ (AACE) also recognized that Lp-PLA2 mass over 223ng/ml could be considered as a part of a global risk assessment strategy for patients with dyslipidemia and other major cardiovascular disease risk factors [31].